Navigation Links
Endologix Receives IDE Approval for Fully Percutaneous Approach to EVAR
Date:11/18/2009

IRVINE, Calif., Nov. 18 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that it has received Investigational Device Exemption (IDE) conditional approval from the United States Food and Drug Administration ("FDA") to begin a prospective, multicenter, randomized clinical trial for a bilateral percutaneous approach to endovascular abdominal aortic aneurysm repair (EVAR) utilizing the Company's IntuiTrak(TM) endovascular delivery system for the Powerlink® family of stent grafts.

Standard EVAR procedures require an open surgical cut-down of one or both femoral arteries for delivery system access and device deployment. Percutaneous EVAR (PEVAR) procedures do not require an open surgical cut-down of either femoral artery, as access to the femoral artery is achieved via a percutaneous ("across the skin") approach. There are currently no medical devices approved by the FDA, or in pivotal clinical trials, for a percutaneous EVAR indication. The Company plans to initiate this first pivotal clinical trial for percutaneous EVAR in the first quarter of 2010. Based on the trial results, Endologix intends to submit a future PMA supplement for a broadened indication for the IntuiTrak endovascular delivery system to include PEVAR in suitable patients and will initiate widespread physician training programs on this technique.

John McDermott, Endologix President and Chief Executive Officer, said, "The approval for our percutaneous EVAR pivotal clinical trial further demonstrates Endologix's commitment to become the innovation leader in the repair of abdominal aortic aneurysms. The unique attributes of our products, including the ease-of-use and low-profile design of the IntuiTrak endovascular system, makes the percutaneous approach possible. In addition, our Powerlink System is the only endovascular stent graft that utilizes anatomical fixation, which has been shown in clinical trials to yield exceptional long-term patient outcomes."

The trial will utilize a "pre-close" technique facilitated by the Prostar® XL Percutaneous Vascular Surgical System or Perclose ProGlide® Suture-Mediated Closure System, both made by Abbott. Up to 20 U.S. clinical sites will enroll 150 patients in the randomized trial. One hundred patients will undergo PEVAR with closure facilitated by either the Prostar XL or Perclose ProGlide device, and 50 patients will undergo standard surgical cut-down EVAR. All patients will be treated with the IntuiTrak endovascular delivery system.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink® System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. Additional information can be found on Endologix's Web site at www.endologix.com.

Forward-Looking Statements

Except for historical information contained herein, this news release contains forward-looking statements, specifically with respect to the initiation and timing of clinical trials, and the possible outcomes there from. Please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and the Company's other filings with the Securities and Exchange Commission, for more detailed information regarding regulatory and clinical risks and other factors that may cause actual results to differ materially from those expressed or implied.


    COMPANY CONTACT:                           INVESTOR CONTACTS:
    ----------------                           ------------------
    Endologix, Inc.                            The Ruth Group
    John McDermott, CEO                        Nick Laudico (646) 536-7030
    (949) 595-7200                             Zack Kubow   (646) 536-7020
    www.endologix.com

SOURCE Endologix, Inc.


'/>"/>
SOURCE Endologix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Endologix to Present at Three Upcoming Conferences
2. Endologix Announces Pricing of Public Offering of Common Stock
3. Endologix Reports 42% Second Quarter 2009 Revenue Growth
4. Endologix to Report Second Quarter 2009 Financial Results on July 22, 2009
5. Endologix Added to Russell Indexes
6. Endologix Announces Live Web Cast of Presentation in SMH Capital Small Cap Spotlight on June 17, 2009 at 4:15 p.m. ET
7. Endologix Receives Nasdaq Letter on Director Independence
8. Endologix Announces Full Commercial Launch of IntuiTrak Express Delivery System
9. SHPS Receives Re-Accreditation from URAC for Consumer Education and Support Program
10. Guided Care receives Award for Innovation in Practice Improvement
11. Mississippi Baptist Medical Center Receives American College of Cardiology Foundation's NCDR ACTION Registry-GWTGTM Gold Performance Achievement Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Qualidigm , the ... headquarters to a new, more expansive office space in order to accommodate its ... a distressed office building in Wethersfield, Conn. located at 936 Silas Deane Highway ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Executives, Staff & ... money to for the Toys for Tots Literacy Campaign at their Semi-Annual Graduation and ... of $70 billion, the U.S. ranks at number 14 internationally in literacy. Statistically, a ...
(Date:3/28/2017)... ... , ... Public relations pros work hard to earn placements and build ... many results are clear, much of PR is hard to quantify. Goal-setting and measurement ... measurement, firms should always take an all-inclusive approach that takes both traditional and non-traditional ...
(Date:3/28/2017)... ... March 28, 2017 , ... Thank you to all who attended ... , This event was exclusive to providers and offered an opportunity to collaborate ... place at the Manchester Grand Hyatt where attendees gathered for a lively discussion on ...
(Date:3/27/2017)... ... March 27, 2017 , ... The respected ... who want straight teeth without the extensive time commitment and aesthetic disadvantages of ... acquiring a referral. A custom-designed series of virtually invisible aligners are created for ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... TEL-AVIV, Israel , March 27, 2017 /PRNewswire/ ... TASE: THXBY), a specialty clinical-stage pharmaceutical company specializing in the ... of its public offering in the ... Shares (ADSs), each ADS representing 40 ordinary shares ... per ADS. In addition, Therapix has granted the ...
(Date:3/27/2017)... LightIntegra Technology Inc. today announced that its ... President and Chief Executive Officer effective March 13, 2017. ... Directors of LightIntegra. Paul Geyer will continue ... "This is the perfect time for Bill ... We,ve selected a very strong leader at a time ...
(Date:3/27/2017)...  A new survey from the American ... Bidding Program (CBP) significantly reduced beneficiary choice and access ... choice forces beneficiaries to switch to unfamiliar or unsuitable ... AADE,s survey is the latest in a ... out the inherent problems with the CBP. Last year, ...
Breaking Medicine Technology: